Guidant/Lilly ReoPro marketing alliance will provide support to interventional cardiologists for PTCA.
Executive Summary
GUIDANT/LILLY MARKETING ALLIANCE FOR CENTOCOR's REOPRO will provide customer education to interventional cardiology clinicians in support of Lilly's Feb. 9 launch of Centocor's percutaneous transluminal coronary angioplasty adjunct ReoPro (c7E3, abciximab), Guidant announced March 20. Under terms of the agreement, Guidant's Advanced Cardiovascular Systems "will support Lilly's 67 dedicated cardiovascular representatives" during the ReoPro launch via ACS Clinical Application Consultants. ReoPro was approved Dec. 22 as an adjunctive therapy to prevent ischemic complications in PTCA patients at high risk for abrupt vascular closure following surgery ("The Pink Sheet" Jan. 2, p. 16).